This Tiny Danish Biotech Is Betting Against the Hottest Drug Strategy in Medicine

On those counts, the results were positive. AT7687 was described as "well-tolerated and suitable for once-weekly subcutaneous injection" in both healthy volunteers and people living with obesity. That's the green light Antag needed to advance into Phase 2a studies, which are expected to begin in mid-2026.

The company hasn't released detailed numbers yet (no weight-loss percentages, no adverse event tables, no dose-response curves). Full data will likely come through a future publication or investor presentation. But clearing Phase 1 without safety red flags is meaningful for a first-in-class drug targeting a receptor that nobody has blocked in humans before.

Think of it this way: they just proved you can pull this particular lever in the human body without something breaking.

Why Both Pushing and Pulling the Same Lever Can Work

The GIP receptor story contains a genuine scientific paradox. Both activating it (agonism) and blocking it (antagonism) seem to produce weight loss and metabolic improvements in animal models. That sounds impossible, like saying both the gas pedal and the brake make a car go faster.

The resolution lies in tissue specificity and timing. Activating GIPR works through one set of brain circuits (GABAergic neurons, for the neuroscience fans) that suppress appetite independently of GLP-1. Blocking GIPR works through a completely different neural pathway that actually depends on GLP-1 signaling. Same receptor, opposite pharmacology, different wiring.

In preclinical monkey studies, AT7687 kept obese animals' weight stable while placebo animals gained about 8.6% body weight over 42 days. When combined with a GLP-1 drug (liraglutide), the combo produced even better results: insulin dropped 52%, glucose fell 30%, and LDL cholesterol plunged 48% versus placebo. Those are animal numbers, not human data, but they paint a compelling picture of what the combination could do.

The $84 Million Question

Antag isn't operating on fumes. In December 2024, the company closed an €80 million Series A (roughly $84 million) led by Versant Ventures, with Novo Holdings, SR One Capital Management, and a KKR-backed vehicle called Dawn Biopharma joining the round. That's serious money for a company with a single clinical asset.

The funding is earmarked for AT7687's clinical development, including planned combination studies with a GLP-1 agonist. That combination angle is strategically smart: if blocking GIP while boosting GLP-1 proves superior to GLP-1 alone, Antag would have a differentiated product in the fastest-growing drug market on Earth.

The company, a spinout from the University of Copenhagen founded in 2017, was built on the incretin research of Prof. Jens Juul Holst (co-discoverer of GLP-1) and Prof. Mette M. Rosenkilde, who identified a naturally occurring GIP antagonist. Their academic pedigree is essentially the scientific equivalent of having invented the wheel and then deciding to build a car.

Who Needs a Plan B?

More people than you'd think. Roughly 10% to 17% of patients on GLP-1 drugs like semaglutide don't achieve meaningful weight loss. About 10% of the general population carries genetic variants associated with GLP-1 resistance. And gastrointestinal side effects (nausea, vomiting, bloating) drive a meaningful number of patients to quit therapy altogether.

For those non-responders and the GI-intolerant crowd, a mechanistically different approach isn't a luxury; it's a necessity. GIPR antagonism could offer a path for patients whose biology simply doesn't cooperate with the agonist playbook.

The Road Ahead Is Long (and Narrow)

Antag still has enormous amounts to prove. Phase 1 safety data, while encouraging, tells you almost nothing about whether the drug actually produces clinically meaningful weight loss in humans. Phase 2a will be the first real test of efficacy, and even optimistic timelines put definitive answers years away.

The competitive landscape is also brutal. Tirzepatide has billions in sales and years of clinical data. Triple agonists (GLP-1/GIP/glucagon) are advancing through multiple pipelines. Antag is showing up to a gunfight with a promising but unproven weapon.

Still, the history of medicine is full of cases where the contrarian approach turned out to be right. Beta-blockers were once considered dangerous for heart failure patients; now they're standard of care. The question isn't whether GIPR antagonism can work (the biology is provocative). It's whether it works well enough, in the right patients, at the right dose, to carve out real market share.

Antag just proved the first part: you can safely block this receptor in humans. Now comes the hard part: proving it matters.

CAR-T Just Broke Into the Liver Cancer Club

A Shanghai biotech just got the green light for the first-ever randomized CAR-T trial in liver cancer. The early data: a 50% response rate in patients who had run out of options. If it works, it could crack open the solid tumor door that CAR-T has been banging on for a decade.